Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Rev. int. sci. méd. (Abidj.) ; 8(1): 55-60, 2006. tab
Artigo em Francês | AIM (África) | ID: biblio-1269184

RESUMO

Contexte : Le diabète sucré, notamment le type 2 est responsable de complications dégénératives en particulier la neuropathie. L'atteinte vésicale neuropathique qui est la cystopathie est l'objet de notre travail. Objectif : Décrire les facteurs de risque pouvant influencer l'apparition de la cystopathie. Matériel et méthodes : Il s'agissait d'une étude transversale prospective à visée descriptive qui s'est déroutée du 19 juin au 19 juillet 2005 au centre antidiabétique d'Abidjan (CADA). Elle a porté sur une population de 74 diabétiques régulièrement suivis au CADA. Résultats : Il en ressort une prédominance du diabète de type 2 avec 89,2%, un âge moyen de 50 ans et prédominance du sexe masculin avec un sex-ratio de 2,7. Les données cliniques sont caractérisées par une prévalence des troubles urinaires estimée à 20,3%, une prédominance de la dysurie soit 66,7% par rapport à l'ensemble des troubles urinaires. Les facteurs de risque cardio-vasculaires existent dans cette population de diabétique, avec 31% d'hypertension artérielle, 24,3% de dyslipidémie et 17,6% d'obésité. Nos patients ont un mauvais équilibre glycémique avec une valeur moyenne de l'hémoglobine glyquée à 8,3% .La glycémie joue un rôle essentiel dans l'apparition de la cystopathie. Conclusion : Les facteurs cardiovasculaire (hypertension, dyslipidémie et obésité) existent dans notre série mais n'influencent pas l'apparition de la cystopathie. C'est le mauvais équilibre glycémique qui joue un rôle essentiel. La réalisation d'une échographie suspubienne à travers la mesure des volumes pré et post mictionnel est d'un apport utile au diagnostic


Assuntos
Côte d'Ivoire , /complicações , Neuropatias Diabéticas
3.
Chemotherapy ; 45(6): 452-65, 1999.
Artigo em Inglês | MEDLINE | ID: mdl-10567776

RESUMO

An annual 20% excess mortality rate is observed in HIV-seropositive patients after treatment for tuberculosis. An affordable secondary prophylaxis against main opportunistic diseases is needed, i.e. against tuberculosis, toxoplasmosis, pneumocystosis and other infections occurring in this target population. This open prospective randomized study assessed morbidity and mortality in 2 cohorts of HIV-seropositive patients having recently recovered from pulmonary tuberculosis: 134 patients assigned to prophylactic treatment with isoniazid (INH, 300 mg once daily) plus sulphadoxine-pyrimethamine (S, 500 mg/P, 25 mg once weekly), and 129 were controls, comparable for sex, age, weight and HIV-serology. Patients were followed-up for up to 2 years: 192 person-years (PY) in the prophylaxis group and 142 PY in the control group. Four patients developed tuberculosis and 20 patients died in the prophylaxis group, compared to 10 and 23 controls, respectively. Sick days were reported by 22 patients in the prophylaxis group and by 77 patients in the control group. This prophylaxis was associated with a moderate decrease of mortality (log rank test: p = 0.1736), a significant decrease of tuberculosis incidence (log rank test: p = 0. 0234), a highly significant reduction of adverse events and sick days, and a prevention of wasting (p = 0.008) and anaemia (p = 0. 045). No death from toxoplasmosis occurred in the prophylaxis group as compared to 2 possible cases among controls; toxoplasmosis IgG levels declined in treated patients, but increased in controls (p = 0.01). There was no adverse drug reaction due to SP (10,006 doses) or to INH. Compliance with SP intake was good, but moderate as with INH intake. We conclude that a secondary prophylaxis with INH+SP represents a cost-effective measure to improve health conditions of HIV-infected adults in Côte d'Ivoire, following a full treatment course against tuberculosis.


Assuntos
Infecções Oportunistas Relacionadas com a AIDS/tratamento farmacológico , Isoniazida/administração & dosagem , Pirimetamina/administração & dosagem , Sulfadoxina/administração & dosagem , Tuberculose Pulmonar/tratamento farmacológico , Adulto , Peso Corporal , Quimioterapia Combinada , Feminino , Humanos , Isoniazida/efeitos adversos , Masculino , Cooperação do Paciente , Estudos Prospectivos , Pirimetamina/efeitos adversos , Sulfadoxina/efeitos adversos , Tuberculose Pulmonar/microbiologia , Tuberculose Pulmonar/mortalidade
4.
Med Trop (Mars) ; 48(1): 65-7, 1988.
Artigo em Francês | MEDLINE | ID: mdl-2835570

RESUMO

Three new cases of systemic lupus erythematosus, all observed en 1986, are reported. So the incidence of this disease seems to be increased. Clinical features do not show any particularity and hyperthermia; cutaneous manifestations, arthralgia and renal impairment must be emphasized. Urinary infection is frequent. Among the biological features, antinuclear antibodies are positive in the three cases. Glucocorticosteroid therapy was efficient at short term, with unfortunately side effects which lead to stop the treatment.


Assuntos
Lúpus Eritematoso Sistêmico/diagnóstico , Adulto , Côte d'Ivoire , Feminino , Glucocorticoides/uso terapêutico , Humanos , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Lúpus Eritematoso Sistêmico/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA